Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Titel:
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Auteur:
Rudin, Charles M Pietanza, M Catherine Bauer, Todd M Ready, Neal Morgensztern, Daniel Glisson, Bonnie S Byers, Lauren A Johnson, Melissa L Burris III, Howard A Robert, Francisco Han, Tae H Bheddah, Sheila Theiss, Noah Watson, Sky Mathur, Deepan Vennapusa, Bharathi Zayed, Hany Lally, Satwant Strickland, Donald K Govindan, Ramaswamy Dylla, Scott J Peng, Stanford L Spigel, David R